Recombinant Antibody Development for Brain Tumors

Intracranial tumors can occur in any structure or cell type of the central nervous system. The most common primary brain tumors are meningiomas (27%) and glioblastomas (23%). Many of these tumors are aggressive and of high grade. Antibodies are an effective treatment for brain tumors. The process of constructing monoclonal antibodies by traditional methods takes 6-8 months. Due to the increasing need for faster access to antibodies, the demand for recombinant antibodies for brain tumor applications is also increasing.

We offer recombinant antibody development services for brain tumors

Recombinant antibodies are monoclonal antibodies constructed in vitro by synthesizing genes. Alfa Cytology first isolates the heavy and light chains of the antibody and integrates them into a DNA expression vector. The integrated plasmid is then transfected into the host expression system for expression. The obtained recombinant antibodies (chimeric antibodies, humanized antibodies, fully humanized antibodies, small molecule antibodies, and bispecific antibodies) can be used in the field of brain tumor research, and the antibody production time is reduced to 1-2 months.

Target gene synthesis service for brain tumors

• Synthesis of antibody heavy and light chain sequences
• Construction of antibody heavy and light chain sequences into recombinant antibody expression vectors
• Sequencing validation
• Endotoxin-free plasmid extraction

Vector construction services

• Transient transfection of HEK293/CHO cells
• Recombinant brain tumor antibody purification
• Recombinant brain tumor antibody quality control (SDS-PAGE and UV analysis)
• Recombinant brain tumor antibody validation (ELISA for immunogen detection)

Large-scale expression service for recombinant brain tumor antibodies

• Transient transfection of HEK293/CHO cells
• Poly/monoclonal recombinant antibody expression stabilization cell line screening
• Large-scale production of recombinant brain tumor antibodies
• Recombinant brain tumor antibody purification
• Recombinant brain tumor antibody quality control (SDS-PAGE and UV analysis)
• Recombinant brain tumor antibody validation (ELISA for immunogen detection)

General service flow

Our successful development cases

• Successfully developed recombinant antibodies specific to β-amyloid termini
• Successfully developed anti-neuronal recombinant antibodies and specific cell membrane antigen antibodies
• Successfully expressed anti-LGI1 recombinant antibody, an anti-Caspr2 recombinant antibody, anti-NMDAR recombinant antibody

Our advantages

• Higher batch stability and purity with minimal background signal.
• Can perform recombinant modification, including antibody fragment expression, isotype substitution, chimeric antibodies, antibody humanization, etc.
• Rapid preparation of large quantities of antibodies can be achieved without the use of animals, thus overcoming ethical concerns for animals.

There is still a great need for recombinant antibody research in brain tumors. Alfa Cytology provides a full range of technical services from gene synthesis to expression of recombinant brain tumor antibodies. We can provide large-scale production services of recombinant antibodies from milligram level to gram level to meet customers' high throughput and high-level production requirements. We are dedicated to finding new targets of molecules that trigger brain tumors and developing antibodies for scientific use. Please contact our staff to learn how we can serve you.